Medtronic PLC (MDT) Business Profile

What it does

Medtronic is a healthcare technology company headquartered in Galway, Ireland. Founded in 1949, it develops, manufactures, distributes and sells device-based medical therapies and related services. Its three reportable segments are the Cardiovascular Portfolio, Neuroscience Portfolio and Medical Surgical Portfolio.

The Cardiovascular Portfolio serves specialists treating heart-rhythm disorders, heart failure, valve disease, aortic disease, coronary disease, peripheral vascular disease and hypertension. Its offerings include pacemakers, defibrillators, cardiac monitoring systems, ablation catheters, heart valves, stents, balloons, vascular grafts and renal-denervation systems.

The Neuroscience Portfolio supplies surgeons and other specialists with spinal implants, surgical imaging, navigation and robotic guidance systems, stroke and aneurysm treatments, ear, nose and throat technologies, pelvic-health therapies, neurostimulators and drug-infusion systems. The Medical Surgical Portfolio supplies surgical stapling, vessel-sealing, wound-closure, endoscopy, robotic-surgery, patient-monitoring and airway-management products.

The company also has all-other operations and transition agreements associated with exited, divested or separating businesses. Its Diabetes Business develops insulin pumps, continuous glucose-monitoring systems and consumables for Type 1 and Type 2 diabetes, but it is no longer a reportable segment following MiniMed’s initial public offering in March 2026.

How it makes money

Medtronic earns revenue by selling medical devices, implants, disposable procedure products, monitoring systems, software-enabled services and related therapies. Its Cardiovascular Portfolio spans implanted cardiac devices and leads, atrial-fibrillation ablation systems, remote monitoring, transcatheter and surgical heart valves, aortic repair systems, coronary stents, vascular balloons and venous-disease treatments. The portfolio also includes care-management and catheterization-lab managed services.

Its Neuroscience Portfolio sells capital equipment and procedure technologies, including surgical imaging, navigation, robotic guidance, power instruments and implants for spinal and cranial procedures. It also sells neurovascular devices, ENT products, pelvic-health systems, spinal-cord and brain-modulation systems, infusion pumps, and products used in vertebral-fracture and tumor procedures.

Medical Surgical sells advanced staplers, energy instruments, mesh, sutures, endoscopy products, the Hugo robotic-assisted surgery system, operating-room video and analytics technology, patient monitoring and airway-management products. Some revenue comes from consumable products used in procedures, including stapler reloads, catheters, sensors, leads, stents, balloons, sutures and implants. A portion of revenue is generated from consignment inventory maintained at hospitals.

Cardiovascular net sales were $14.0 billion in fiscal year 2026, up 12 percent from fiscal year 2025. The provided information does not state consolidated company net sales or a latest-quarter total. Starting in the fourth quarter of fiscal year 2026, the Diabetes Business was no longer a reportable segment, and earlier net sales were recast to conform to that presentation.

Customers and how it sells

Medtronic serves healthcare systems, physicians, clinicians and patients in more than 150 countries. Its customers include hospitals, ambulatory surgical centers, physician offices, home-care and long-term-care facilities, as well as other alternate-site providers. Cardiovascular products are used by electrophysiologists, cardiologists, heart-failure specialists, surgeons, interventional cardiologists and radiologists. Neuroscience customers include spinal surgeons, neurosurgeons, neurologists, pain specialists, orthopedic surgeons, urologists and ENT specialists.

The company sells globally through direct sales representatives and third parties, including independent distributors and agents. Its marketing and sales teams are generally organized around physician specialties, and it establishes enterprise accounts where purchasing dynamics support a portfolio-level relationship. Medical supply products are marketed to materials managers, group purchasing organizations and integrated delivery networks; these organizations can negotiate supply contracts for member facilities.

Medtronic is not dependent on any one customer for more than 10 percent of total net sales. International markets are an area of focus because the company considers them under-penetrated. Its workforce includes 95,000 employees, with 43% based in the U.S. or Puerto Rico.

Suppliers and costs

Medtronic manufactures products at facilities in various countries and buys components and raw materials from numerous suppliers in multiple countries. Certain components and raw materials are available only from a sole supplier. The company works with suppliers on continuity-of-supply measures, quality and reliability, but regulatory manufacturing requirements can limit its ability to establish replacement sources quickly after an interruption.

Its cost base includes product manufacturing, research and development, sales and distribution, clinical evidence generation, regulatory compliance and investment in manufacturing facilities and equipment. Research and development includes improving existing therapies, expanding approved uses, developing new technologies and procedures, and pursuing collaborations, investments, licensing arrangements and acquisitions. The company participates in hundreds of clinical trials each fiscal year.

Cost and margin pressures can also arise from tender pricing, reimbursement conditions, centralized purchasing, hospital vendor rationalization, tariffs, currency movements, inflation, energy and transportation costs. Based on tariff rates as of June 3, 2026, the company estimates a pre-tax net tariff impact of $250 million in fiscal year 2027, excluding possible government refunds.

Competitive position

Medtronic competes in therapeutic and diagnostic medical markets in more than 150 countries. Its product lines face large manufacturers with multiple business lines, smaller manufacturers with narrower product selections, and providers of other therapies, including pharmaceutical companies producing glucagon-like peptide-1s. The company also competes against alternative medical therapies.

Competition depends on product performance and reliability, technology and innovation, safety and quality, breadth of product lines, support services, supply availability, customer service, cost-effectiveness, price and reimbursement approval. Provider consolidation, managed care, tender pricing and centralized hospital purchasing have increased customer price sensitivity. Hospitals may also reduce the number of vendors participating in purchasing programs.

No individual competitor is named as competing with Medtronic in the provided company information.

Our reading: The breadth of therapies across cardiovascular, neuroscience and surgical care is a meaningful moat source because it supports portfolio-level enterprise accounts and cross-selling complementary products. [item1]

Our reading: Direct specialty sales teams and relationships with physicians and healthcare customers are a meaningful moat source, but purchasing consolidation and vendor limits can reduce their effect. [item1]

Our reading: Patents, trade secrets, licenses and clinical evidence support the business, but the company operates amid extensive intellectual-property litigation and rapid technological change. [item1]

Growth opportunities

Medtronic’s growth efforts center on innovation in its existing therapies, new product launches, expansion into large healthcare opportunities, greater use of data, AI and automation, and increasing adoption internationally. The company aims to use AI and data analytics to tailor therapies in real time, facilitate remote monitoring and care delivery, and create standards of care.

Its research and development work includes product enhancements, new indications and applications, less-invasive therapies and new technologies for emerging markets. The company also pursues external collaborations, investments, licensing arrangements and acquisitions to obtain technologies and capabilities. It participates in hundreds of clinical trials each fiscal year to generate clinical and economic evidence.

In Cardiovascular, fiscal 2026 growth included broad business growth, with Cardiac Rhythm & Heart Failure net sales rising 17 percent. Cardiac Ablation Solutions grew through the pulsed-ablation portfolio, partly offset by declines in cryoablation. Growth in Cardiac Rhythm Management included Micra leadless pacemakers, the Aurora extravascular implantable cardioverter-defibrillator system and the SelectSecure 3830 lead.

The company also identifies international markets as an opportunity because it considers them under-penetrated. Its business metrics in the reported period include the Diabetes Business and may not be directly comparable with future periods following that business’s separation.

Structural risks

• Medtronic operates in a highly competitive industry. Its ability to compete depends on product performance, technology and innovation, product safety and quality, product breadth, supply availability, customer support, price, cost-effectiveness and reimbursement approval.

• Products are subject to extensive regulation covering development, testing, manufacturing, labeling, marketing, distribution and post-market surveillance. Adverse regulatory action may limit marketing and sales, delay approvals or require changes to business practices and operations.

• The company depends on global manufacturing and suppliers, including sole-source suppliers for certain components and materials. Regulatory requirements may prevent it from quickly adding or replacing sources after supply interruptions.

• Healthcare cost-containment measures, reimbursement policies, competitive bidding, tender pricing, purchasing consolidation and hospital vendor limits can reduce prices, coverage, demand and customer willingness to pay.

• Global trade policy, tariffs, export controls, sanctions, currency movements, inflation and geopolitical conflicts can raise costs, disrupt supply chains and affect sales. The company estimates a pre-tax net tariff impact of $250 million in fiscal year 2027 based on rates as of June 3, 2026, excluding possible refunds.

• The ongoing separation of the Diabetes Business may be delayed or may not be completed as contemplated, and transition activities, costs, infrastructure arrangements and related disposition steps could affect results and financial condition.

Bottom line

Our reading

Our reading: Medtronic is a global, diversified medical-device business built around specialist therapies, procedure products, implants, capital equipment and supporting services across cardiovascular, neuroscience and surgical care. [item1]

Our reading: Its breadth, specialty sales model, intellectual-property base and clinical-development activity support its competitive position, while reimbursement pressure, procurement consolidation, regulation, supply dependencies and trade costs remain material constraints. [item1; item1a; item7]

Our reading: The Diabetes separation changes segment reporting and can affect comparability with future periods. [item1; item7]